Lipid-Modifying Drugs: Pharmacology and Perspectives.
Adv Exp Med Biol
; 1177: 133-148, 2020.
Article
en En
| MEDLINE
| ID: mdl-32246446
ABSTRACT
Coronary artery disease (CAD) is one of the leading causes of death worldwide. It is well known that dyslipidemia is a major pathogenic risk factor for atherosclerosis and CAD, which results in cardiac ischemic injury and myocardial infarction. Lipid-modifying drugs can effectively improve lipid abnormalities including reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) or increasing high-density lipoprotein cholesterol (HDL-C), and eventually decrease the incidence of cardiovascular events. This chapter will review basic principles of lipid metabolism and focus on the therapeutic strategies of lipids modifying drugs (statins, proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, niacin, polyunsaturated fatty acids, and so on) in patients with arteriosclerotic cardiovascular disease. Meanwhile, the challenges and perspectives of the lipid-lowering agents currently in clinical practice as well as their limitations will be outlined.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Lípidos
/
Hipolipemiantes
Tipo de estudio:
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Adv Exp Med Biol
Año:
2020
Tipo del documento:
Article
País de afiliación:
China